Literature DB >> 15760099

Selective and validated spectrophotometric methods for the determination of nicorandil in pharmaceutical formulations.

Nafisur Rahman1, Yasmin Ahmad, Syed Najmul Hejaz Azmi.   

Abstract

Two simple and sensitive validated spectrophotometric methods have been described for the assay of nicorandil in drug formulations. Method A is based on the reaction of the drug with phloroglucinol-sulfanilic acid reagent in sulfuric acid medium to give yellow-colored product, which absorbs maximally at 425 nm. Method B uses the oxidative coupling of 3-methyl-2-benzothiazolinone hydrazone hydrochloride (MBTH) with DL- 3,4 - dihydroxyphenylalanine (DL-dopa) in the presence of nicorandil as oxidant in sulfuric acid medium to form an intensely colored product having maximum absorbance at 530 nm. Beer's law is obeyed in the concentration range 2.5 to 50.0 and 1.0 to 15.0 microg mL(-1) with methods A and B, respectively. Both methods have been successfully applied for the analysis of drug in pharmaceutical formulations. The reliability and the performance of the proposed methods are established by point and interval hypothesis and through recovery studies. The experimental true bias of all samples is smaller than +/-2%.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15760099      PMCID: PMC2751230          DOI: 10.1208/aapsj060434

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  15 in total

1.  Determination of nicorandil concentrations in human plasma using liquid chromatography.

Authors:  A Ojha; A Pargal
Journal:  J Pharm Biomed Anal       Date:  1999-10       Impact factor: 3.935

2.  Determination of ternary mixtures of antibiotics, by ratio-spectra zero-crossing first- and third-derivative spectrophotometry.

Authors:  B Morelli
Journal:  J Pharm Biomed Anal       Date:  1995-03       Impact factor: 3.935

Review 3.  Nicorandil. An updated review of its use in ischaemic heart disease with emphasis on its cardioprotective effects.

Authors:  A Markham; G L Plosker; K L Goa
Journal:  Drugs       Date:  2000-10       Impact factor: 9.546

4.  Determination of nicorandil in plasma using high-performance liquid chromatography with photoconductivity and ultraviolet detection. Application to pre-clinical pharmacokinetics in beagle dogs.

Authors:  F J Schwende; R C Lewis
Journal:  J Chromatogr       Date:  1990-01-26

5.  Pharmacokinetics of nicorandil, a new coronary vasodilator, in dogs.

Authors:  T Ishizaki; K Chiba; T Suganuma; T Sasaki; H Kamiyama; H Nakano
Journal:  J Pharm Sci       Date:  1984-04       Impact factor: 3.534

Review 6.  Nicorandil. A review of its pharmacology and therapeutic efficacy in angina pectoris.

Authors:  J Frampton; M M Buckley; A Fitton
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546

7.  High-performance liquid chromatographic method for stability and pharmacokinetic studies of nicorandil.

Authors:  E L Bachert; H L Fung
Journal:  J Chromatogr       Date:  1993-09-22

8.  Pharmacokinetic profile of nicorandil in humans: an overview.

Authors:  A Frydman
Journal:  J Cardiovasc Pharmacol       Date:  1992       Impact factor: 3.105

9.  Simultaneous determination of ceftriaxone and streptomycin in mixture by 'ratio-spectra' 2nd derivative and 'zero-crossing' 3rd derivative spectrophotometry.

Authors:  B Morelli
Journal:  Talanta       Date:  1994-05       Impact factor: 6.057

10.  Pharmacokinetics of nicorandil.

Authors:  A M Frydman; P Chapelle; H Diekmann; R Bruno; J J Thebault; J Bouthier; H Caplain; W Ungethuem; C Gaillard; A Le Liboux
Journal:  Am J Cardiol       Date:  1989-06-20       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.